antibody recruiting molecule NK cell combination therapy / Green Cross Cell, AlphaTON Capital - LARVOL DELTA

Biohaven Pharmaceuticals reports first quarter 2020 financial results and recent business developments (PRNewswire) - "The vazegepant trial in COVID-19 associated pulmonary inflammation has been initiated and the first several patients treated. Kleo Pharmaceuticals pursuing monoclonal antibody enhancers (MATEs) to neutralize COVID-19 virus and other small molecule, novel anti-viral approaches....Kleo Pharmaceuticals, Inc. announced a research collaboration with South Korea-based Green Cross LabCell (GCLC) to rapidly advance testing of both companies' technology platforms in combination as a potential therapy for COVID-19 patients. Kleo will combine its antibody recruiting molecule technology with GCLC's off the shelf natural killer (NK) cell therapy. "

Licensing / partnership • Trial status • Infectious Disease • Novel Coronavirus Disease